Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
10.68
Nov 18 • 11:21 AM ET Dollar change+0.01 Percentage change(0.05%)
Today, 6:39 AMFDA says Summit Therapeutics should run a new ivonescimab trial, citing concerns beyond lack of significant overall-survival benefit
Index
RUI
Market Cap
8.52B
Enterprise Value
7.91B
Income
-832.68M
Sales
0.00M
Book/sh
0.71
Cash/sh
0.79
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
265
IPO
Mar 05, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
15.12
P/C
13.52
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
5.99
Current Ratio
5.99
Debt/Eq
0.04
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-1.07
EPS next Y
-1.02
EPS next Q
-0.31
EPS this Y
25.59%
EPS next Y
4.76%
EPS next 5Y
22.59%
EPS past 3/5Y
-52.45% -13.76%
Sales past 3/5Y
- -
EPS Y/Y TTM
13.96%
Sales Y/Y TTM
-
EPS Q/Q
16.26%
Sales Q/Q
-
Insider Own
80.92%
Insider Trans
1.23%
Inst Own
17.18%
Inst Trans
2.61%
ROA
-174.46%
ROE
-220.01%
ROIC
-143.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-29.03%
SMA50
-33.39%
SMA200
-33.69%
Trades
Shs Outstand
799.73M
Shs Float
152.63M
52W High
29.23 -63.48%
52W Low
10.53 1.38%
Volatility
10.87% 8.29%
ATR (14)
1.34
RSI (14)
32.01
Beta
-1.35
Rel Volume
3.28
Avg Volume
6.51M
Volume
6,843,963
Perf Week
-35.85%
Perf Month
-33.65%
Perf Quarter
-14.12%
Perf Half Y
-40.33%
Perf YTD
-38.97%
Perf Year
-36.50%
Perf 3Y
453.11%
Perf 5Y
94.09%
Perf 10Y
1.65%
Prev Close
10.67
Price
10.68
Change %
0.05%
Consensus
Buy
Avg. Price Target
$29.45
Implied Upside
+175.9%
Analysts16incl. previous ratings
Rating Distribution10 Buy · 5 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
TodayDowngrade
BBernstein
Mkt Perform → Underperform$8.30-22.2%
Sep 09, 2026Upgrade
JEF logoJJefferies
Hold → Buy$25+134.2%
Aug 25, 2026Upgrade
BBernstein
Underperform → Mkt Perform$11.90+11.5%
Aug 12, 2026Upgrade
LLeerink Partners
Underperform → Market Perform$13+21.8%
May 22, 2026Downgrade
HH.C. Wainwright
Buy → Neutral
Apr 08, 2026Initiated
SF logoSStifel
Buy$45+321.5%
Mar 16, 2026Downgrade
JEF logoJJefferies
Buy → Hold$15+40.5%
Dec 17, 2025Upgrade
BCS logoBBarclays
Underweight → Equal Weight$18+68.6%
Nov 18, 2025Initiated
WWolfe Research
Peer Perform
Sep 17, 2025Initiated
BCS logoBBarclays
Underweight$13+21.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DUGGAN ROBERT WCo-Chief Executive OfficerNov 16 '26Option Exercise1.06500,000530,000531,000Nov 16 08:26 PM
Zanganeh MahkamCo-Chief Executive OfficerNov 16 '26Option Exercise1.06500,000530,000531,000Nov 16 08:23 PM
Soni Manmeet SinghCOO and CFONov 16 '26Option Exercise1.37100,000137,0003,224,375Nov 16 07:49 PM
Zanganeh MahkamCo-Chief Executive OfficerJun 12 '26Buy13.123,810,00049,987,200573,883,879Jun 12 02:35 PM
DUGGAN ROBERT WCo-Chief Executive OfficerJun 12 '26Buy13.123,810,00049,987,200573,883,879Jun 12 12:28 PM
DUGGAN ROBERT WCo-Chief Executive OfficerJun 04 '26Buy14.60100,0001,460,00025,824,474Jun 04 06:08 PM
Zanganeh MahkamCo-Chief Executive OfficerJun 04 '26Buy14.60100,0001,460,00025,824,474Jun 04 05:45 PM
Soni Manmeet SinghCOO and CFOJun 04 '26Buy14.4550,000722,2503,123,603Jun 04 04:40 PM
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
Co-CEO & Executive ChairmanMr. Robert W. Duggan
M.B.A.Dr. Mahkam Zanganeh D.D.S.
COOMr. Manmeet Singh Soni CPA
FRS CBEProf. Kay Elizabeth Davies DBE
Chief Accounting Officer & Head of FinanceMr. Bhaskar Anand